How to treat liver metastases in colorectal cancer: A review

키워드

참고문헌 (29)

1. Martin J, "Colorectal liver metastases : current management and future perspectives", World J Clin Oncol, 11, pp.761~808 (2020)
2. Dueland S, "Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases", Ann Surg, 271, pp.212~218 (2020)
3. Petrowsky H, "First long-term oncologic results of the ALPPS procedure in a large cohort of patients with colorectal liver metastases", Ann Surg, 272, pp.793~800 (2020)
4. Fong Y, "Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer : analysis of 1001consecutive cases", Ann Surg, 230, pp.309~318 (1999)
5. Viganò L, "Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases", Ann Surg Oncol, 19, pp.2786~2796 (2012)
6. Karagkounis G, "Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases", Cancer, 119, pp.4137~4144 (2013)
7. Osumi H, "RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy", Int J Cancer, 139, pp.803~811 (2016)
8. Teng HW, "BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy", J Surg Oncol, 106, pp.123~129 (2012)
9. Margonis GA, "Genetic And Morphological Evaluation(GAME)score for patients with colorectal liver metastases", Br J Surg, 105, pp.1210~1220 (2018)
10. Nordlinger B, "Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial", Lancet, 371, pp.1007~1016 (2008)
11. Nordlinger B, "Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial", Lancet Oncol, 14, pp.1208~1215 (2013)
12. Benson AB, "Colon Cancer, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 19, pp.329~359 (2021)
13. Ayez N, "The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases : clinical risk score as possible discriminator", Eur J Surg Oncol, 41, pp.859~867 (2015)
14. Boudjema K, "Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: a prospective, open-label, randomized, controlled trial", Ann Surg, 273, pp.49~56 (2021)
15. Reddy SK, "Timing of multimodality therapy for resectable synchronous colorectal liver metastases : a retrospective multi-institutional analysis", Ann Surg Oncol, 16, pp.1809~1819 (2009)
16. Pinto Marques H, "Peri-operative chemotherapy for resectable colorectal liver metastasis : does timing of systemic therapy matter?", J Surg Oncol, 105, pp.511~519 (2012)
17. Bonney GK, "Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; an international multi-center data analysis using LiverMetSurvey", J Surg Oncol, 111, pp.716~724 (2015)
18. Nordlinger B, "Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases : recommendations from an expert panel", Ann Oncol, 20, pp.985~992 (2009)
19. Schmoll HJ, "ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making", Ann Oncol, 23, pp.2479~2516 (2012)
20. Van Cutsem E, "ESMO consensus guidelines for the management of patients with metastatic colorectal cancer", Ann Oncol, 27, pp.1386~1422 (2016)
21. Primrose J, "Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis : the New EPOC randomised controlled trial", Lancet Oncol, 15, pp.601~611 (2014)
22. Del Mastro L, "Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-OvestMammella Intergruppo (GONO-MIG) Group", Ann Oncol, 19, pp.299~307 (2008)
23. Cremolini C, "FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer : updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study", Lancet Oncol, 16, pp.1306~1315 (2015)
24. Gruenberger T, "Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer : the OLIVIA multinational randomised phase II trial", Ann Oncol, 26, pp.702~708 (2015)
25. Cremolini C, "Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial", Lancet Oncol, 21, pp.497~507 (2020)
26. Van Cutsem E, "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", N Engl J Med, 360, pp.1408~1417 (2009)
27. Heinemann V, "FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer(FIRE-3) : a randomised, open-label, phase 3 trial", Lancet Oncol, 15, pp.1065~1075 (2014)
28. Venook AP, "Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer : a randomized clinical trial", JAMA, 317, pp.2392~2401 (2017)
29. Adam R, "The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus", Oncologist, 17, pp.1225~1239 (2012)

관련 논문AI추천